Idiopathic granulomatous mastitis: TNFi effectivity in a retrospective inception cohort

dc.contributor.authorLermi, Nihal
dc.contributor.authorEkin, Ali
dc.contributor.authorYagiz, Burcu
dc.contributor.authorYildirim, Fatih
dc.contributor.authorAlbayrak, Fatih
dc.contributor.authorSunkak, Saliha
dc.contributor.authorDalkilic, Ediz
dc.date.accessioned2026-08-12T17:26:41Z
dc.date.issued2025
dc.departmentFırat Üniversitesi
dc.description.abstractObjectivesIdiopathic granulomatous mastitis is a rare, chronic, inflammatory breast disease that can mimic breast carcinoma. Histologicaly there are giant cells and epitheloid histiocytes forming non-caseating granulomas. Corticosteroids, methotrexate, azathioprine, intralesional corticosteroid injection can be used as the first step drugs in the treatment of patients with Idiopathic granulomatous mastitis, but the next step is unclear in a group of patients who are resistant to these treatments. Many of these patients also undergo unnecessary surgical interventions. Tumor necrosis factor-alpha (TNF-alpha) plays a role in maintaining the granuloma structure. There is few case reports and very limited data in the literature regarding TNF-alpha inhibitor treatment in resistant patients. Our aim is to show that TNF-alpha inhibitors may be an alternative for refractory patients in the treatment of idiopathic granulomatous mastitis.MethodsThe data of 25 female patients with idiopathic granulomatous mastitis who were refractory to conventional therapies and started TNF-alpha inhibitors were retrospectively analyzed. Pre- and post-treatment M scores of the patients were calculated.ResultsWe observed that the M-scores of our patients decreased as the duration of TNF-alpha inhibitors use increased.ConclusionOur study contains the largest number of patients with data on the use of TNF-alpha inhibitors in the treatment of idiopathic granulomatous mastitis. We believe that our study will contribute to the development of idiopathic granulomatous mastitis treatment algorithms.Key Points center dot TNF-alpha inhibitors may be an alternative for refractory patients in the treatment of idiopathic granulomatous mastitis.ConclusionOur study contains the largest number of patients with data on the use of TNF-alpha inhibitors in the treatment of idiopathic granulomatous mastitis. We believe that our study will contribute to the development of idiopathic granulomatous mastitis treatment algorithms.Key Points center dot TNF-alpha inhibitors may be an alternative for refractory patients in the treatment of idiopathic granulomatous mastitis.
dc.identifier.doi10.1007/s10067-025-07468-y
dc.identifier.endpage2560
dc.identifier.issn0770-3198
dc.identifier.issn1434-9949
dc.identifier.issue6
dc.identifier.orcid0000-0002-8295-9770
dc.identifier.orcid0000-0002-6052-3896
dc.identifier.orcid0000-0001-9945-8940
dc.identifier.orcid0000-0003-3692-1293
dc.identifier.orcid0000-0003-4995-430X
dc.identifier.pmid40314853
dc.identifier.scopus2-s2.0-105003970350
dc.identifier.scopusqualityQ1
dc.identifier.startpage2553
dc.identifier.urihttps://doi.org/10.1007/s10067-025-07468-y
dc.identifier.urihttps://hdl.handle.net/11508/54923
dc.identifier.volume44
dc.identifier.wosWOS:001480168800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer London Ltd
dc.relation.ispartofClinical Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectIdiopathic granulomatous mastitis
dc.subjectAdalimumab
dc.subjectTumor necrosis factor inhibitors
dc.subjectRecurrence
dc.titleIdiopathic granulomatous mastitis: TNFi effectivity in a retrospective inception cohort
dc.typeArticle

Dosyalar